Recommendations on dermatologic surgery during the COVID-19 pandemic - 19/06/20
Doi : 10.1016/j.jaad.2020.04.034
Samuel Antranig Der Sarkissian, FRACGP a, b, Leo Kim, FRACS c, Michael Veness, FRANZCR d, Eleni Yiasemides, FACD e, Deshan Frank Sebaratnam, FACD a, c, f, ⁎ 
a Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales
b Faculty of Medicine, University of Wollongong, Wollongong, New South Wales
c The Skin Hospital, Westmead, New South Wales
d Department of Radiation Oncology, Westmead Hospital, Westmead, New South Wales
e SouthDerm, Kogarah, New South Wales
f Faculty of Medicine, University of New South Wales, Kensington, New South Wales, Australia
∗Correspondence to: Deshan Sebaratnam, FACD, Department of Dermatology, Liverpool Hospital, 45-47 Goulburn St, Liverpool, NSW 2170, AustraliaDepartment of DermatologyLiverpool Hospital45-47 Goulburn StLiverpoolNSW2170Australia
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 83 - N° 1
P. e29-e30 - luglio 2020 Ritorno al numero
Articolo precedente
- Reply to: “Evidence-based guidelines for tuberculosis screening before biologic treatment initiation”
- Anthony P. Fernandez, Ariana Ellis, Urmi Khanna, AbdulAziz Galadari
- Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
- Alecia Blaszczak, John C.L. Trinidad, Alexander M. Cartron
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.